News
PHIOW
0.0232
+36.47%
0.0062
PHIO PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CELL AND GENE THERAPY (ASCGT)
Reuters · 6d ago
PHIO PHARMACEUTICALS REPORTS 2023 YEAR END FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 04/02 11:30
Phio Pharmaceuticals Corp <PHIO.OQ> expected to post a loss of $1.30 a share - Earnings Preview
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share - Earnings Preview. The one available analyst rating on the shares is "buy" The company is expected to report results on April 1 for the period ending December 31 2023.
Reuters · 03/29 11:03
Phio Pharmaceuticals Corp <PHIO.OQ> expected to post a loss of $1.30 a share - Earnings Preview
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share. The one available analyst rating on the shares is "buy" Wall Street's median 12-month price target for the company is $4.00. Phio expected to report results on March 20.
Reuters · 03/18 11:03
BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, J.B. Hunt, Bristol-Myers
The s&p 500 and the nasdaq were set to open higher on thursday. Alphabet shares were the top percentage gainers on the nyse. Dow e-minis were down 0.02% and nasdaq 100 up 0.59%. J.b. Hunt, bristol-myers and dollar general were among the day's losers.
Reuters · 12/07/2023 14:18
BUZZ-U.S. STOCKS ON THE MOVE-Tempest Therapeutics, Ally Financial, Phio Pharmaceuticals
Reuters · 10/11/2023 17:07
BUZZ-U.S. STOCKS ON THE MOVE-Myriad Genetics, Arista Networks, DaVita
Reuters · 10/11/2023 15:10
BRIEF-Phio Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Business Update
Reuters · 05/11/2023 21:30
BRIEF-Phio Pharmaceuticals Files For Offering 353,983 Shares Of Common Stock To Several Institutional Investors Pursuant To Prospectus Supplement
Reuters · 04/19/2023 21:15
More
Webull provides a variety of real-time PHIOW stock news. You can receive the latest news about PHIO PHARMACTCL through multiple platforms. This information may help you make smarter investment decisions.
About PHIOW
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.